122 related articles for article (PubMed ID: 26745035)
1. β-Adrenergic Receptors : New Target in Breast Cancer.
Wang T; Li Y; Lu HL; Meng QW; Cai L; Chen XS
Asian Pac J Cancer Prev; 2015; 16(18):8031-9. PubMed ID: 26745035
[TBL] [Abstract][Full Text] [Related]
2. Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis.
Caparica R; Bruzzone M; Agostinetto E; De Angelis C; Fêde Â; Ceppi M; de Azambuja E
ESMO Open; 2021 Apr; 6(2):100066. PubMed ID: 33639601
[TBL] [Abstract][Full Text] [Related]
3. β-Blockers Reduce Breast Cancer Recurrence and Breast Cancer Death: A Meta-Analysis.
Childers WK; Hollenbeak CS; Cheriyath P
Clin Breast Cancer; 2015 Dec; 15(6):426-31. PubMed ID: 26516037
[TBL] [Abstract][Full Text] [Related]
4. Is Beta-Blocker Use Beneficial in Breast Cancer? A Meta-Analysis.
Kim HY; Jung YJ; Lee SH; Jung HJ; Pak K
Oncology; 2017; 92(5):264-268. PubMed ID: 28132057
[TBL] [Abstract][Full Text] [Related]
5. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.
Powe DG; Voss MJ; Zänker KS; Habashy HO; Green AR; Ellis IO; Entschladen F
Oncotarget; 2010 Nov; 1(7):628-638. PubMed ID: 21317458
[TBL] [Abstract][Full Text] [Related]
6. Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies.
Yap A; Lopez-Olivo MA; Dubowitz J; Pratt G; Hiller J; Gottumukkala V; Sloan E; Riedel B; Schier R
Br J Anaesth; 2018 Jul; 121(1):45-57. PubMed ID: 29935594
[TBL] [Abstract][Full Text] [Related]
7. β-Blocker Use and Risk of Recurrence in Patients with Early Breast Cancer.
Sakellakis M; Kostaki A; Starakis I; Koutras A
Chemotherapy; 2014; 60(5-6):288-9. PubMed ID: 25998892
[TBL] [Abstract][Full Text] [Related]
8. Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.
Montoya A; Amaya CN; Belmont A; Diab N; Trevino R; Villanueva G; Rains S; Sanchez LA; Badri N; Otoukesh S; Khammanivong A; Liss D; Baca ST; Aguilera RJ; Dickerson EB; Torabi A; Dwivedi AK; Abbas A; Chambers K; Bryan BA; Nahleh Z
Oncotarget; 2017 Jan; 8(4):6446-6460. PubMed ID: 28031536
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.
Watkins JL; Thaker PH; Nick AM; Ramondetta LM; Kumar S; Urbauer DL; Matsuo K; Squires KC; Coleman RL; Lutgendorf SK; Ramirez PT; Sood AK
Cancer; 2015 Oct; 121(19):3444-51. PubMed ID: 26301456
[TBL] [Abstract][Full Text] [Related]
10. The role of adrenergic signaling in breast cancer biology.
Obeid EI; Conzen SD
Cancer Biomark; 2013; 13(3):161-9. PubMed ID: 23912488
[TBL] [Abstract][Full Text] [Related]
11. Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.
Cardwell CR; Pottegård A; Vaes E; Garmo H; Murray LJ; Brown C; Vissers PA; O'Rorke M; Visvanathan K; Cronin-Fenton D; De Schutter H; Lambe M; Powe DG; van Herk-Sukel MP; Gavin A; Friis S; Sharp L; Bennett K
Breast Cancer Res; 2016 Dec; 18(1):119. PubMed ID: 27906047
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women.
Botteri E; Munzone E; Rotmensz N; Cipolla C; De Giorgi V; Santillo B; Zanelotti A; Adamoli L; Colleoni M; Viale G; Goldhirsch A; Gandini S
Breast Cancer Res Treat; 2013 Aug; 140(3):567-75. PubMed ID: 23912960
[TBL] [Abstract][Full Text] [Related]
13. Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study.
Shah SM; Carey IM; Owen CG; Harris T; Dewilde S; Cook DG
Br J Clin Pharmacol; 2011 Jul; 72(1):157-61. PubMed ID: 21453301
[TBL] [Abstract][Full Text] [Related]
14. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
15. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract][Full Text] [Related]
16. Beta blockers and breast cancer mortality: a population- based study.
Barron TI; Connolly RM; Sharp L; Bennett K; Visvanathan K
J Clin Oncol; 2011 Jul; 29(19):2635-44. PubMed ID: 21632503
[TBL] [Abstract][Full Text] [Related]
17. Beta-adrenergic blockers and breast cancer.
Med Lett Drugs Ther; 2012 Jan; 54(1382):6-7. PubMed ID: 22267215
[No Abstract] [Full Text] [Related]
18. Beta blockade as adjunctive breast cancer therapy: A review.
Phadke S; Clamon G
Crit Rev Oncol Hematol; 2019 Jun; 138():173-177. PubMed ID: 31092374
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of MMP Family Members Functions as Prognostic Biomarker for Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Ren F; Tang R; Zhang X; Madushi WM; Luo D; Dang Y; Li Z; Wei K; Chen G
PLoS One; 2015; 10(8):e0135544. PubMed ID: 26270045
[TBL] [Abstract][Full Text] [Related]
20. Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: Evidence from observational studies.
Zhao Y; Wang Q; Zhao X; Meng H; Yu J
Clin Exp Hypertens; 2018; 40(1):22-27. PubMed ID: 29115847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
